Hoth Therapeutics, Inc. (HOTH)

NASDAQ: HOTH · IEX Real-Time Price · USD
1.260
-0.040 (-3.08%)
Feb 27, 2024, 11:12 AM EST - Market open
-3.08%
Market Cap 5.63M
Revenue (ttm) n/a
Net Income (ttm) -9.62M
Shares Out 4.35M
EPS (ttm) -4.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,684
Open 1.260
Previous Close 1.300
Day's Range 1.254 - 1.300
52-Week Range 0.990 - 4.300
Beta 0.61
Analysts Strong Buy
Price Target 7.63 (+505.56%)
Earnings Date Apr 1, 2024

About HOTH

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 15, 2019
Employees 2
Stock Exchange NASDAQ
Ticker Symbol HOTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for HOTH stock is "Strong Buy." The 12-month stock price forecast is $7.63, which is an increase of 505.56% from the latest price.

Price Target
$7.63
(505.56% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers NEW YORK , Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (N...

1 day ago - PRNewsWire

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

NEW YORK , Feb. 13, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO CE...

14 days ago - PRNewsWire

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics NEW YORK , Jan. 18, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focuse...

5 weeks ago - PRNewsWire

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies

NEW YORK , Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance HT...

3 months ago - PRNewsWire

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

Hoth intends to continue development under Orphan Drug Designation NEW YORK , Nov. 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today t...

3 months ago - PRNewsWire

Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023

NobleCon is the preeminent showcase of small and microcap companies NEW YORK , Nov. 10, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that R...

3 months ago - PRNewsWire

Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery

The new wholly owned subsidiary will screen for rare disease therapeutics. NEW YORK , Oct. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, ...

5 months ago - PRNewsWire

FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients

NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the Pre-IND meeting requested on September 8 th for HT-KIT ...

5 months ago - PRNewsWire

Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

NEW YORK , Sept. 15, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a patient-focused biopharmaceutical company, today announced the closing of its previously a...

5 months ago - PRNewsWire

Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the p...

5 months ago - PRNewsWire

Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT. HT-KIT Shows Positive Results in AML Positive Preclinical Results of Novel HT-KIT Therapeutic Perfo...

5 months ago - PRNewsWire

Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients

HT-KIT received Orphan Drug Designation from FDA for its mRNA Frame Shifting Cancer Therapeutic Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggress...

6 months ago - PRNewsWire

Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa

78% of patients reported that their overall health had improved since starting BioLexa as compared to 22% stating that there was no change in their health, or their health was worse. DLQI found that B...

6 months ago - PRNewsWire

Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease

HT-ALZ Showed Improvement on Several Tests of Cognitive Function HT-ALZ Showed Positive Benefits with Reductions in Anxiety Completed Dose Response Study Leads Hoth to Begin Formulation Development NE...

7 months ago - PRNewsWire

Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial

NEW YORK , July 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that the first patient has been dosed in its Phase 2...

7 months ago - PRNewsWire

Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic

FDA Approved Trial Now Has Two Sites Approved with Additional Sites in Approval Process Recruitment of Patients to Accelerate NEW YORK , July 19, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: ...

7 months ago - PRNewsWire

Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site

Hoth achieves milestone of multiple sites to host trial NEW YORK , June 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced to...

9 months ago - PRNewsWire

Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease

Higher Dosing Shows Positive Effects on Cognitive Function NEW YORK , June 6, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical  company, today announced...

9 months ago - PRNewsWire

Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge

Hoth to Concentrate on its Current Pipeline and Continue Phase 2 Clinical Study Hoth Has Over Twelve Months Cash on Balance Sheet NEW YORK , May 12, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDA...

10 months ago - PRNewsWire

HOTH THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Hoth Therapeutics, Inc. - HOTH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Hoth Therapeut...

10 months ago - Business Wire

HOTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Hoth Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Algorithm Sciences, Inc. is fair to Hoth sha...

10 months ago - Business Wire

Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge

Anthony Zook, formerly of Astra Zeneca, to be named Chairman of The Board Mike Tilton to be named Chief Executive Officer of the Combined Company Algorithm pipeline focused on Pulmonary Arterial Hyper...

10 months ago - PRNewsWire

Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

NEW YORK , March 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the activation of Washington University School of Medicine...

1 year ago - PRNewsWire

Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity

Strengthens Measures to Safeguard Shareholder Interests through ShareIntel's Investigation and Due Diligence Services for Illegal Short Selling NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Hoth Therapeuti...

1 year ago - PRNewsWire

Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model and Results Show Reduced Anxiety and Improved Performance NEW YORK , Feb. 8, 2023 /PRNewswire/ -- Hoth Therapeutics, ...

1 year ago - PRNewsWire